research use only
Cat.No.S1093
| Related Targets | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Other IGF-1R Inhibitors | Linsitinib (OSI-906) BMS-536924 NVP-AEW541 BMS-754807 Picropodophyllin (AXL1717) AG-1024 NVP-ADW742 NT157 PQ 401 Ginsenoside Rg5 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| NIH3T3 cells | Function assay | Inhibition of human insulin receptor autophosphorylation in transfected mouse NIH3T3 cells, IC50=19 nM | ||||
| human TC71 cells | Proliferation assay | 72 h | Antiproliferative activity against human TC71 cells after 72 hrs by Celltiter assay, IC50=35 nM | |||
| human SK-ES cells | Proliferation assay | 72 h | Antiproliferative activity against human SK-ES cells after 72 hrs by Celltiter assay, IC50=61 nM | |||
| human NCI-H929 cells | Proliferation assay | 72 h | Antiproliferative activity against human NCI-H929 cells after 72 hrs by Celltiter assay, IC50=81 nM | |||
| human LP-1 cells | Proliferation assay | 72 h | Antiproliferative activity against human LP-1 cells after 72 hrs by Celltiter assay, IC50=104 nM | |||
| human COLO205 cells | Proliferation assay | 72 h | Antiproliferative activity against human COLO205 cells after 72 hrs by Celltiter assay, IC50=124 nM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 124 mg/mL
(145.54 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 851.96 | Formula | C44H47F2N9O5S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1089283-49-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | GSK 4529 | Smiles | CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F | ||
| Targets/IC50/Ki |
Insulin Receptor
(Cell-free assay) 25 nM
IGF-1R
(Cell-free assay) 27 nM
|
|---|---|
| In vitro |
GSK1904529A is a reversible, ATP-competitive inhibitor and has enzyme-inhibitor binding values against IGF-1R and IR with Ki of 1.6 nM and 1.3 nM, respectively. This compound potently inhibits the ligand-induced phosphorylation of IGF-1R and IR at concentrations above 0.01 μM, followed by blocking downstream signaling (AKT, IRS-1, and ERK). It potently inhibits NIH-3T3/LISN, TC-71, SK-N-MC, SK-ES RD-ES cells with IC50 of 60 nM, 35 nM, 43 nM, 61 nM and 62 nM, respectively. This inhibitor also inhibits other multiple myeloma and Ewing's sarcoma cell lines including NCI-H929, MOLP-8, LP-1 and KMS-12-BM etc. It induces cell cycle arrest at the G1 phase in cell lines COLO 205, MCF-7, and NCI-H929, which are sensitive to this compound.
|
| Kinase Assay |
Kinase assays
|
|
GSK1904529A is dissolved in DMSO as stock solution at 10 mM. Baculovirus-expressed glutathione S-transferase-tagged proteins encoding the intracellular domain of IGF-1R (amino acids 957-1367) and IR (amino acids 979-1382) are used for determination of IC50. Kinases are activated by preincubating the enzyme (2.7 μM final concentration) in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1mg/mL bovine serum albumin, and 2 mM ATP. This compound is diluted in DMSO and dispensed into the assay plates (100 nL/well). Kinase reactions contained (in 10 μL) 50 mM HEPES (pH 7.5), 3 mM DTT, 0.1mg/mL bovine serum albumin, 1mM CHAPS, 10 mM MgCl2, 10 μM ATP, 500 nM substrate peptide (biotin-aminohexylAEEEEYMMMMAKKKK-NH2; QPC), and 0.5 nM activated enzyme. Reactions are stopped after 1 hour at room temperature with 33 μM EDTA. Peptide phosphorylation is measured by time-resolved fluorescence resonance energy transfer with 7 nM streptavidin Surelight allophycocyanin and 1nM europium-conjugated phosphotyrosine antibodies. Plates are read in a multilabel reader.
|
|
| In vivo |
GSK1904529A indicates 98% tumor growth inhibition in NIH-3T3/LISN tumor-bearing mice at a dose of 30 mg/kg (orally, twice-daily) and 75% in COLO 205 xenografts mice (once daily). Among HT29 and BxPC3 xenografts, this compound produces moderate tumor growth inhibition with no side effects at a dose of 30 mg/kg. Meanwhile, it shows minimal effects on blood glucose levels. This compound (~3.5 μM in blood) completely inhibits IGF-1R phosphorylation. It has been implicated in treatment of various IGF-1R-dependent tumors including prostate, colon, breast, pancreatic, ovarian, and sarcomas.
|
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Growth inhibition assay | Cell number |
|
28572530 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.